Assessment of reported adverse events after substitution between TNF alfa inhibitors biosimilars in the WHO pharmacovigilance database

被引：0
作者：
Orhon, P. [1 ]
Robert, M. [1 ]
Bernardeau, C. [1 ]
Fusaroli, M. [2 ]
Roustit, M. [3 ]
Cracowski, J. L. [1 ]
Khouri, C. [1 ]
机构：
[1] Grenoble Alpes Univ Hosp, Pharmacovigilance Unit, Grenoble, France
[2] Dept Med & Surg Sci, Pharmacol Unit, Bologna, Italy
[3] Grenoble Alpes Univ Hosp, Clin Pharmacol Dept, Grenoble, France
来源：
FUNDAMENTAL & CLINICAL PHARMACOLOGY | 2023年 / 37卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PS-115
引用
收藏
页码：160 / 160
页数：1
相关论文
共 50 条
  • [21] OPHTHALMOLOGICAL ADVERSE EVENTS UNDER JAK INHIBITORS IN PATIENTS WITH RHEUMATOID ARTHRITIS: CASE ANALYSIS OF THE EUROPEAN PHARMACOVIGILANCE DATABASE
    Hecquet, Sophie
    Rabier, Marie Blanche
    Lepelley, Marion
    Verhoeven, Frank
    Gauthier, Anne Sophie
    Prati, Clement
    Delbosc, Bernard
    Wendling, Daniel
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 748 - 748
  • [22] Cardiovascular adverse events associated with JAK inhibitor versus TNF inhibitor: A disproportionality analysis in national pharmacovigilance database of Korea
    Yoon, Jinkyoung
    Yang, Bo Ram
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 475 - 475
  • [23] Pharmacovigilance assessment of the association between Fournier's gangrene and other severe genital adverse events with SGLT-2 inhibitors
    Fadini, Gian Paolo
    Sarangdhar, Mayur
    De Ponti, Fabrizio
    Avogaro, Angelo
    Raschi, Emanuel
    BMJ OPEN DIABETES RESEARCH & CARE, 2019, 7 (01)
  • [24] Antibiotics-Induced Liver Injury: A Pharmacovigilance Study Using a Measure of Disproportionality in a Database of Spontaneously Reported Adverse Events
    Mendes, D.
    Dias, P.
    Alves, C.
    Batel-Marques, F.
    DRUG SAFETY, 2015, 38 (10) : 1006 - 1006
  • [25] Safety profiles of adalimumab, etanercept and infliximab: a pharmacovigilance study using a measure of disproportionality in a database of spontaneously reported adverse events
    Mendes, D.
    Alves, C.
    Batel-Marques, F.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2014, 39 (03) : 307 - 313
  • [26] Serious adverse events reported with benzimidazole derivatives: A disproportionality analysis from the World Health Organization's pharmacovigilance database
    Modingam, Pamella
    Faillie, Jean-Luc
    Campillo, Jeremy T.
    PLOS NEGLECTED TROPICAL DISEASES, 2024, 18 (11):
  • [27] Safety of BRAF and MEK Inhibitors for Treatment of Metastatic melanoma: Analysis of the WHO Database of Adverse Events
    Rousset, M.
    Gouverneur, A.
    Arnaud, M.
    Claraz, P.
    Fourrier-Reglat, A.
    Pariente, A.
    Miremont-Salame, G.
    Molimard, M.
    DRUG SAFETY, 2017, 40 (10) : 972 - 973
  • [28] Adverse events following the use of immune checkpoint inhibitors: An analysis of the WHO VigiAccess database.
    Nikita, Nikita
    Zinner, Ralph
    Johnson, Jennifer Maria
    Ghosh, Natasha
    Wilson, Melissa
    Lu-Yao, Grace L.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [29] Favipiravir Use in COVID-19: Analysis of Suspected Adverse Drug Events Reported in the WHO Database
    Kaur, Rimple Jeet
    Charan, Jaykaran
    Dutta, Siddhartha
    Sharma, Paras
    Bhardwaj, Pankaj
    Sharma, Praveen
    Lugova, Halyna
    Krishnapillai, Ambigga
    Islam, Salequl
    Haque, Mainul
    Misra, Sanjeev
    INFECTION AND DRUG RESISTANCE, 2020, 13 : 4427 - 4438
  • [30] The Burden of Cardiac Adverse Events Associated With Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors: A Large Pharmacovigilance Database Analysis
    Thakre, Anuj
    Babbili, Akhilesh
    Thotamgari, Sahith Reddy
    Grewal, Udhayvir
    Beedupalli, Kavitha
    Dominic, Paari
    CIRCULATION, 2022, 146
12345